Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:08:27.958Z.
Calculation as of: 2026-10-06T19:08:27.958Z.
Quote observation: 2026-10-06T19:04:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2b785bc55096390182f69d3a0e2d020d3bb9b84e75505e860cfcb21a76503d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
TriSalus Life Sciences, Inc.
Market Cap
$270.31M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$273.53M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.95M
EV/EBIT Ratio
N/A
TTM Avg
27.51x
3Y Avg
26.71x
5Y Avg
33.46x
Market Cap
$269.97M
EV/EBIT Ratio
N/A
TTM Avg
102.60x
3Y Avg
102.60x
5Y Avg
102.60x
Market Cap
$265.98M
EV/EBIT Ratio
N/A
TTM Avg
2223.35x
3Y Avg
2223.35x
5Y Avg
2223.35x
Market Cap
$267.20M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.68M
EV/EBIT Ratio
N/A
TTM Avg
11.31x
3Y Avg
11.31x
5Y Avg
15.93x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $270.31M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $273.53M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $269.95M | N/A | 27.51x | 26.71x | 33.46x |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.97M | N/A | 102.60x | 102.60x | 102.60x |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.89M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $265.98M | N/A | 2223.35x | 2223.35x | 2223.35x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $267.20M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | N/A | 11.31x | 11.31x | 15.93x |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
